2017 American Transplant Congress » Concurrent Session: Pediatric Liver

2:30pm-2:42pm

Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma.

M. Kueht,¹ S. Commander,¹ T.-A. Ha,¹ A. Rana,^1,2 Y. Shi,¹ S. Vasudevan,^1,2 J. Goss.^1,2

2:42pm-2:54pm

Personalizing Immunosuppression with Molecular Phenotyping in Pediatric Liver Transplantation.

M. Ningappa, C. Ashokkumar, Q. Sun, B. Higgs, K. Soltys, G. Bond, G. Mazariegos, R. Sindhi.

2:54pm-3:06pm

Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.

S. Antala, L. Bow, R. Morotti, G. Gan, D. Yanhong, U. Ekong, S. Emre.

3:06pm-3:18pm

Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study.

A. Weymann,¹ R. Ganschow,¹ B. Ericzon,¹ A. Dhawan,¹ K. Sharif,¹ E.-D. Martzloff,² B. Rauer,² J. Ng,² P. Lopez.²

3:18pm-3:30pm

20 and 25-Year Outcomes Following Pediatric Liver Transplantation.

W. Andrews,¹ N. Gupta,² U. Ekong.³

3:30pm-3:42pm

Impact of Peri-Transplant Viral Upper Respiratory Infection on Pediatric Liver Transplant Outcomes.

J. Kohler,¹ T. Miloh,¹ K. Hosek,¹ J. Goss,² F. Munoz.¹

3:42pm-3:54pm

Assessing Self-Efficacy During the Transition from Pediatric to Adult Liver Transplant Care.

J. Bilhartz, M. Lopez, S. Eder, E. Fredericks.